Felix Hoffmann, Wilhelm Roehl, Hans Andersag and Walter Kikuth, Gerhard Domagk, Otto Bayer, Hermann Schnell, Friedrich Bossert, Wulf Vater -- researchers and scientists who made history. They were responsible for pioneering inventions that revolutionized medicine, chemistry and materials development: Aspirin™, Germanin™, Resochin™, sulfonamides, and Adalat™.
These outstanding scientists all had one thing in common: they established Bayer's reputation as an innovation company. Bayer retains a strong commitment to this tradition. The Group’s realignment enables us to focus on areas where innovation is the driving force: health care, nutrition and high-tech materials.
Innovation plays a major role in addressing the global challenges of providing health care and nutrition for the world’s growing population and conserving dwindling resources. It is a key driver of future growth at Bayer.
Innovation and the skills of our employees form the basis for our success as a company. We drive innovation by continuously developing new molecules, technologies and business models in our research centers, investing in research and development projects, supporting the development of our employees and expanding our activities through acquisitions or collaborations with external partners. Strengthening our innovative capability enables us to address the challenges of our time and achieve profitable corporate growth.
In 2015 a total of €4.281 billion was spent on research and development. This was equivalent to 9.1 percent of sales. Approximately 14,700 employees worldwide work in this field.
Through this pooling of expertise, Bayer aims to rapidly translate new ideas into successful products. These activities are also supported by systematic employee development in the company’s research and development units.